WARNINGS AND PRECAUTIONS
For current labeling information, please visit endstream endobj 315 0 obj <> endobj 310 0 obj <>stream q 1 0 0 1 -8.728516 -1.877228 cm 0 0 612 792 re W n 1 0 0 1 8.728516 1.877228 cm BT /GS0 gs /TT0 1 Tf 12 0 0 12 63.2715 47.6228 Tm ( )Tj 19 -0.005 Td (13)Tj 0.0007 Tc -0.0007 Tw -19 54.94 Td [(pectoris, dizziness, nausea\) upon initiation of sexua)-4 (l activity should be advised to refrain from)8.5 ( )]TJ 0.0008 Tc -0.0008 Tw 0 -1.165 TD (further activity and should discuss the episode with their physician. )Tj 0 Tc 0 Tw T* ( )Tj 0.0008 Tc -0.0008 Tw T* (Physicians should advise patients to stop use )Tj 0.0003 Tc -0.0003 Tw (of all PDE5 inhibitors, including VIAGRA, and )Tj 0.0006 Tc -0.0006 Tw T* [(seek m)8.4 (e)-0.6 (dical attention in the event of a sudden loss of vision in one or both e\ yes. Such an event )]TJ 0.001 Tc -0.001 Tw T* [(m)8.8 (ay be a sign of non-arteritic anterior ischem)8.8 (ic)]TJ 0.0005 Tc -0.0005 Tw 18.99 0 Td ( optic neuropathy \(NAION\), a cause of decreased )Tj 0.0008 Tc -0.0008 Tw -18.99 -1.165 Td [(vision including perm)8.6 (anent loss of vision, that has been reported rarely post-m)8.6 (arketing in )]TJ T* [(tem)8.6 (poral association with the use of all PDE5 inhibitors. It is not possibl\ e to determ)8.6 (ine whether )]TJ 0.0009 Tc -0.0009 Tw T* (these events are related directly to the use of PD)Tj 0.0008 Tc -0.0008 Tw 19.335 0 Td (E5 inhibitors or to other factors. Physicians )Tj 0.0009 Tc -0.0009 Tw -19.335 -1.165 Td (should also discuss with patients the increased )Tj 0.0003 Tc -0.0003 Tw 18.84 0 Td (risk of NAION in individuals who have already )Tj 0.0005 Tc -0.0005 Tw -18.84 -1.165 Td (experienced NAION in one eye, including whether su)Tj 0.0006 Tc -0.0006 Tw 21.57 0 Td (ch individuals could be adversely affected )Tj -21.57 -1.18 Td (by use of vasodilators, such as PDE5 inhibitors \(see )Tj /TT1 1 Tf -0.0003 Tc 0 Tw 21.025 0 Td (POST-MARKETING )Tj 0.0003 Tw -21.025 -1.18 Td (EXPERIENCE/Special Senses)Tj /TT0 1 Tf 0.001 Tc 0 Tw 12.91 0 Td (\).
Non-medical use
Cite this article
)Tj 0 Tc -12.91 -1.165 Td ( )Tj 0.0008 Tc -0.0008 Tw T* (Physicians should advise patients to stop taki)Tj 0.0002 Tc -0.0002 Tw 18.09 0 Td (ng PDE5 inhibitors, including VIAGRA, and seek )Tj 0.0007 Tc -0.0007 Tw -18.09 -1.165 Td [(prom)8.5 (pt m)8.5 (edical attention in the event of sudden decrease or loss of hearing.
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Viagra Generic | 200mg | 60 + 4 Pills | 125.19€ 119.23€ | |
| Viagra Generic | 100mg | 270 + 10 Pills | 270.47€ 257.59€ | |
| Viagra Generic | 50mg | 20 Pills | 40.52€ 38.59€ | |
| Kamagra Polo | 100mg | 32 Pills | 125.88€ 119.89€ | |
| Viagra Generic | 200mg | 20 Pills | 61.69€ 58.75€ | |
| Viagra Generic | 50mg | 270 + 8 Pills | 198.48€ 189.03€ | |
| Kamagra Polo | 100mg | 84 + 4 Pills | 244.49€ 232.85€ | |
| Viagra Generic | 150mg | 90 + 6 Pills | 147.18€ 140.17€ | |
| Viagra Generic | 25mg | 180 + 6 Pills | 154.93€ 147.55€ | |
| Viagra Generic | 25mg | 30 + 4 Pills | 47.97€ 45.69€ | |
| Kamagra Oral Jelly | 100mg | 90 + 8 Sachets | 303.56€ 289.10€ | |
| Viagra Generic | 25mg | 60 + 4 Pills | 71.99€ 68.56€ | |
| Viagra Generic | 150mg | 180 + 10 Pills | 236.46€ 225.20€ | |
| Kamagra Oral Jelly | 100mg | 110 + 9 Sachets | 334.87€ 318.92€ | |
| Kamagra Polo | 100mg | 20 Pills | 83.56€ 79.58€ |
Th\ ese events, which )]TJ 0.0008 Tc -0.0008 Tw T* [(m)8.6 (ay be accom)8.6 (p)0.8 (anied by tinnitus and dizziness, have been reported in tem)8.6 (poral association to the )]TJ 0.0006 Tc -0.0006 Tw T* [(intake of PDE5 inhibitors, including VIAGRA. It is not possible to deter\ m)8.4 (ine whether these )]TJ 0.0008 Tc -0.0008 Tw 0 -1.18 TD (events are related directly to the use of PDE5 inhibitors or to other fa\ ctors \(see )Tj /TT1 1 Tf -0.002 Tc 0 Tw 31.745 0 Td (ADVERSE )Tj 0.0003 Tc -0.0003 Tw -31.745 -1.18 Td (REACTIONS, Clinical Trials and Post-Marketing Experience)Tj /TT0 1 Tf 0.001 Tc 0 Tw 26.46 0 Td (\). )Tj /CS0 cs 1 0 0 scn 0 Tc -26.46 -1.165 Td ( )Tj 0 g 0.0007 Tc -0.0007 Tw 0 -1.165 TD (Physicians should warn patients that prolonged )Tj 0.0009 Tc -0.0009 Tw 19.14 0 Td [(erections greater than 4 hours and priapism)8.7 ( )]TJ 0.0008 Tc -0.0008 Tw -19.14 -1.165 Td [(\(painful erections greater than 6 hours in duration\))-4.3 ( have been reported infrequently since m)8.6 (arket )]TJ 0.0007 Tc -0.0007 Tw T* (approval of VIAGRA.
8.5 Geriatric Use
For current labeling information, please visit endstream endobj 315 0 obj <> endobj 310 0 obj <>stream q 1 0 0 1 -8.728516 -1.877228 cm 0 0 612 792 re W n 1 0 0 1 8.728516 1.877228 cm BT /GS0 gs /TT0 1 Tf 12 0 0 12 63.2715 47.6228 Tm ( )Tj 19 -0.005 Td (13)Tj 0.0007 Tc -0.0007 Tw -19 54.94 Td [(pectoris, dizziness, nausea\) upon initiation of sexua)-4 (l activity should be advised to refrain from)8.5 ( )]TJ 0.0008 Tc -0.0008 Tw 0 -1.165 TD (further activity and should discuss the episode with their physician. )Tj 0 Tc 0 Tw T* ( )Tj 0.0008 Tc -0.0008 Tw T* (Physicians should advise patients to stop use )Tj 0.0003 Tc -0.0003 Tw (of all PDE5 inhibitors, including VIAGRA, and )Tj 0.0006 Tc -0.0006 Tw T* [(seek m)8.4 (e)-0.6 (dical attention in the event of a sudden loss of vision in one or both e\ yes. Such an event )]TJ 0.001 Tc -0.001 Tw T* [(m)8.8 (ay be a sign of non-arteritic anterior ischem)8.8 (ic)]TJ 0.0005 Tc -0.0005 Tw 18.99 0 Td ( optic neuropathy \(NAION\), a cause of decreased )Tj 0.0008 Tc -0.0008 Tw -18.99 -1.165 Td [(vision including perm)8.6 (anent loss of vision, that has been reported rarely post-m)8.6 (arketing in )]TJ T* [(tem)8.6 (poral association with the use of all PDE5 inhibitors. It is not possibl\ e to determ)8.6 (ine whether )]TJ 0.0009 Tc -0.0009 Tw T* (these events are related directly to the use of PD)Tj 0.0008 Tc -0.0008 Tw 19.335 0 Td (E5 inhibitors or to other factors. Physicians )Tj 0.0009 Tc -0.0009 Tw -19.335 -1.165 Td (should also discuss with patients the increased )Tj 0.0003 Tc -0.0003 Tw 18.84 0 Td (risk of NAION in individuals who have already )Tj 0.0005 Tc -0.0005 Tw -18.84 -1.165 Td (experienced NAION in one eye, including whether su)Tj 0.0006 Tc -0.0006 Tw 21.57 0 Td (ch individuals could be adversely affected )Tj -21.57 -1.18 Td (by use of vasodilators, such as PDE5 inhibitors \(see )Tj /TT1 1 Tf -0.0003 Tc 0 Tw 21.025 0 Td (POST-MARKETING )Tj 0.0003 Tw -21.025 -1.18 Td (EXPERIENCE/Special Senses)Tj /TT0 1 Tf 0.001 Tc 0 Tw 12.91 0 Td (\).
Viagra Generic
)Tj 0 Tc -12.91 -1.165 Td ( )Tj 0.0008 Tc -0.0008 Tw T* (Physicians should advise patients to stop taki)Tj 0.0002 Tc -0.0002 Tw 18.09 0 Td (ng PDE5 inhibitors, including VIAGRA, and seek )Tj 0.0007 Tc -0.0007 Tw -18.09 -1.165 Td [(prom)8.5 (pt m)8.5 (edical attention in the event of sudden decrease or loss of hearing. Th\ ese events, which )]TJ 0.0008 Tc -0.0008 Tw T* [(m)8.6 (ay be accom)8.6 (p)0.8 (anied by tinnitus and dizziness, have been reported in tem)8.6 (poral association to the )]TJ 0.0006 Tc -0.0006 Tw T* [(intake of PDE5 inhibitors, including VIAGRA. It is not possible to deter\ m)8.4 (ine whether these )]TJ 0.0008 Tc -0.0008 Tw 0 -1.18 TD (events are related directly to the use of PDE5 inhibitors or to other fa\ ctors \(see )Tj /TT1 1 Tf -0.002 Tc 0 Tw 31.745 0 Td (ADVERSE )Tj 0.0003 Tc -0.0003 Tw -31.745 -1.18 Td (REACTIONS, Clinical Trials and Post-Marketing Experience)Tj /TT0 1 Tf 0.001 Tc 0 Tw 26.46 0 Td (\). )Tj /CS0 cs 1 0 0 scn 0 Tc -26.46 -1.165 Td ( )Tj 0 g 0.0007 Tc -0.0007 Tw 0 -1.165 TD (Physicians should warn patients that prolonged )Tj 0.0009 Tc -0.0009 Tw 19.14 0 Td [(erections greater than 4 hours and priapism)8.7 ( )]TJ 0.0008 Tc -0.0008 Tw -19.14 -1.165 Td [(\(painful erections greater than 6 hours in duration\))-4.3 ( have been reported infrequently since m)8.6 (arket )]TJ 0.0007 Tc -0.0007 Tw T* (approval of VIAGRA. In the event of an erection that persists longer tha\ n 4 hours, the patient )Tj 0.0009 Tc -0.0009 Tw T* [(should seek im)8.7 (m)8.7 (ediate m)8.7 (edical assistance. In the event of an erection that persists longer tha\ n 4 hours, the patient )Tj 0.0009 Tc -0.0009 Tw T* [(should seek im)8.7 (m)8.7 (ediate m)8.7 (edical assistance. If pria)]TJ 0.001 Tc buy pills sildenafil -0.001 Tw [(pism)8.8 ( is not treated im)8.8 (m)8.8 (ediately, penile tissue )]TJ 0.0007 Tc -0.0007 Tw T* [(dam)8.5 (age and perm)8.5 (anent loss of potency m)8.5 (ay result. )]TJ 0 Tc 0 Tw T* ( )Tj 0.0005 Tc -0.0005 Tw T* [(The use of VIAGRA offers no protection against sexually transm)8.3 (itted diseases.
- Sildenafil white is often sold as small, round, white tablets.
- It is available in various formulations, including sublingual and capsules.
- The drug increases cGMP levels, leading to smooth muscle relaxation.
- Generic sildenafil is usually cheaper than brand-name Viagra.
- Erectile dysfunction can be caused by physical or mental health issues.
- Misusing sildenafil white can result in priapism, a painful erection lasting hours.
- Some formulations come with flavoring to improve taste.
- Patient education about correct use is key to safety and effectiveness.
- Sildenafil white does not protect against sexually transmitted infections.
- It is important to avoid taking more than the recommended dose.
- Long-term safety data is still being studied, but generally considered safe when used properly.
Counseling of )]TJ 0.001 Tc -0.001 Tw T* [(patients about the protective m)8.8 (easures necessary to guard against sexually transm)8.8 (itted diseases, )]TJ 0.0005 Tc -0.0005 Tw T* [(including the Hum)8.3 (a)-0.7 (n Im)8.3 (m)8.3 (unodeficiency Virus \(HIV\), m)8.3 (a)-0.7 (y be considered. )]TJ 0 Tc 0 Tw T* ( )Tj /TT1 1 Tf 0.0004 Tc -0.0004 Tw 0 -1.18 TD (Drug Interactions )Tj 0.0002 Tc -0.0002 Tw 0 -1.17 TD (Effects of Other Drugs on VIAGRA )Tj /TT2 1 Tf 0.0009 Tc -0.0009 Tw T* (In vitro)Tj /TT1 1 Tf 0.0006 Tc -0.0006 Tw ( studies:)Tj /TT0 1 Tf 0.001 Tc -0.001 Tw 6.625 0 Td [( Sildenafil m)8.8 (etabolism)8.8 ( is principally )]TJ 0.0005 Tc -0.0005 Tw 14.82 0 Td [(m)8.3 (e)-0.7 (diated by the cytochrom)8.3 (e)-0.7 ( P450 \(CYP\) )]TJ 0.0006 Tc -0.0006 Tw -21.445 -1.165 Td [(isoform)8.4 (s 3A4 \(m)8.4 (ajor route\) and 2C9 \(m)8.4 (inor rout)-1.8 (e\). Therefore, inhibitors of these isoenzym)8.5 (es )]TJ 0.001 Tc -0.001 Tw 0 -1.165 TD [(m)8.8 (ay reduce sildenafil clearance.
Medical uses
For current labeling information, please visit endstream endobj 311 0 obj <> endobj 306 0 obj <>stream q 1 0 0 1 -8.008606 -1.877228 cm 0 0 612 792 re W n 1 0 0 1 8.008606 1.877228 cm BT /GS0 gs /TT0 1 Tf 12 0 0 12 63.9914 47.6228 Tm ( )Tj 19 -0.005 Td (12)Tj 0.0008 Tc -0.0008 Tw -19 54.94 Td [(- In those patients already taking an optim)8.6 (ized dose of a PDE5 inhibitor, alpha-blocker therapy )]TJ 0 -1.165 TD [(should be initiated at the lowest dose. Stepwise increase in alpha-block\ er dose m)8.6 (ay be associated )]TJ 0.0005 Tc -0.0005 Tw T* (with further lowering of blood pressure when taking a PDE5 inhibitor. )Tj T* [(- Safety of com)8.3 (b)0.5 (ined use of PDE5 inhibitors and alpha-blockers m)8.3 (a)-0.7 (y be affected by other )]TJ 0.0009 Tc -0.0009 Tw T* [(variables, including intravascular volum)8.7 (e depletion and other anti-hypertensive drugs. )]TJ 0 Tc 0 Tw T* ( )Tj 0.0007 Tc -0.0007 Tw T* [(Viagra has system)8.5 (ic vasodilatory properties and m)8.5 (ay augm)8.5 (ent the blood pressure lowering effect )]TJ 0.0009 Tc -0.0009 Tw T* [(of other anti-hypertensive m)8.7 (edications. )]TJ 0 Tc 0 Tw T* ( )Tj 0.001 Tc -0.001 Tw T* [(Patients on m)8.8 (u)1 (ltiple antihypertensive m)8.8 (edications were included in the pivotal clinical trials for )]TJ 0.0004 Tc -0.0004 Tw T* (VIAGRA.
Sildenafil Citrate
In a separate drug interaction study, wh)Tj 0.0002 Tc -0.0002 Tw 20.21 0 Td [(en am)8 (lodipine, 5 m)8 (g or 10 m)8 (g, and VIAGRA, )]TJ 0.0008 Tc -0.0008 Tw -20.21 -1.165 Td [(100 m)8.6 (g)0.8 ( were orally adm)8.6 (i)-1.4 (nistered concom)8.6 (itantly to hypertensive patients m)8.6 (ean additional blood )]TJ 0.0007 Tc -0.0007 Tw 0 -1.18 TD [(pressure reduction of 8 m)8.5 (m)8.5 (H)2.9 (g systolic and 7 m)8.5 (m)8.5 (H)2.9 (g diastolic were noted \(see )]TJ /TT1 1 Tf -0.0006 Tc 0 Tw 31.42 0 Td (Drug )Tj 0.0006 Tc -31.42 -1.18 Td (Interactions)Tj /TT0 1 Tf 0.001 Tc 5.175 0 Td (\). )Tj 0 Tc -5.175 -1.165 Td ( )Tj 0.0005 Tc -0.0005 Tw 0 -1.165 TD (The safety of VIAGRA is unknown in patients with bleeding disorders and \ patients with active )Tj 0.001 Tc -0.001 Tw T* (peptic ulceration. )Tj 0 Tc 0 Tw T* ( )Tj 0.0005 Tc -0.0005 Tw T* [(VIAGRA should be used with caution in patients with anatom)8.3 (ical deform)8.3 (ation of the penis \(such )]TJ 0.0008 Tc -0.0008 Tw T* (as angulation, cavernosal fibrosis or Peyronie\222s disease\), or in pat\ ients who have conditions )Tj 0.0009 Tc -0.0009 Tw T* [(which m)8.7 (ay predispose them)8.7 ( to priapism)8.7 ( \(such as sickle cell anem)8.7 (ia, m)8.7 (u)0.9 (ltiple m)8.7 (y)0.9 (elom)8.7 (a, or )]TJ 0 Tw T* [(leukem)8.7 (i)-1.3 (a\). )]TJ 0 Tc T* ( )Tj 0.0003 Tc -0.0003 Tw T* [(The safety and efficacy of com)8.1 (binations of)]TJ 0.0006 Tc -0.0006 Tw 17.16 0 Td [( VIAGRA with other treatm)8.4 (e)-0.6 (nts for erectile )]TJ 0.0005 Tc -0.0005 Tw -17.16 -1.165 Td (dysfunction have not been studied. )]TJ 0 Tc 0 Tw T* ( )Tj /TT2 1 Tf 0.0008 Tc -0.0008 Tw 0 -1.18 TD (In vivo)Tj /TT1 1 Tf 0.0006 Tc -0.0006 Tw 2.865 0 Td ( studies:)Tj /TT0 1 Tf 3.535 0 Td [( Cim)8.5 (etidine \(800 m)8.5 (g)0.7 (\), a nonspecific CYP inhibitor, caused a 56% increase in )]TJ -6.4 -1.165 Td [(plasm)8.4 (a)-0.6 ( sildenafil concentrations when coadm)8.4 (i)-1.6 (nistered with VIAGRA \(50 m)8.4 (g)0.6 (\) to healthy )]TJ 0.0009 Tc 0 Tw 0 -1.165 TD (volunteers.
- Sildenafil white is a common name for the generic version of Viagra.
- It is used to treat erectile dysfunction in men.
- Sildenafil white is known for its rapid onset of action.
- The medication works by enhancing blood flow to the penis.
- It is typically taken about 30 to 60 minutes before sexual activity.
- Sildenafil white is available in various doses, usually 25mg, 50mg, and 100mg.
- The drug should not be used with nitrate medications to avoid dangerous interactions.
- Common side effects include headache, flushing, and nasal congestion.
- It is important to follow dosage instructions provided by a healthcare provider.
- Sildenafil white can cause low blood pressure in some users.
- Store sildenafil white in a cool, dry place, away from direct sunlight.
)Tj 0 Tc T* ( )Tj 0.0001 Tc -0.0001 Tw T* [(W)8.9 (hen a single 100 m)7.9 (g dose of VIAGRA was adm)7.9 (i)]TJ 0.0008 Tc -0.0008 Tw 20.335 0 Td [(nistered with erythrom)8.6 (ycin, a specific )]TJ 0.0007 Tc -0.0007 Tw -20.335 -1.165 Td [(CYP3A4 inhibitor, at steady state \(500 m)8.5 (g)0.7 ( bid for 5 days\), there was a 182% increase in )]TJ T* [(sildenafil system)8.5 (ic exposure \(AUC\).
2.1 Recommended Dosage in Adults
If pria)]TJ 0.001 Tc buy pills sildenafil -0.001 Tw [(pism)8.8 ( is not treated im)8.8 (m)8.8 (ediately, penile tissue )]TJ 0.0007 Tc -0.0007 Tw T* [(dam)8.5 (age and perm)8.5 (anent loss of potency m)8.5 (ay result. )]TJ 0 Tc 0 Tw T* ( )Tj 0.0005 Tc -0.0005 Tw T* [(The use of VIAGRA offers no protection against sexually transm)8.3 (itted diseases. Counseling of )]TJ 0.001 Tc -0.001 Tw T* [(patients about the protective m)8.8 (easures necessary to guard against sexually transm)8.8 (itted diseases, )]TJ 0.0005 Tc -0.0005 Tw T* [(including the Hum)8.3 (a)-0.7 (n Im)8.3 (m)8.3 (unodeficiency Virus \(HIV\), m)8.3 (a)-0.7 (y be considered. )]TJ 0 Tc 0 Tw T* ( )Tj /TT1 1 Tf 0.0004 Tc -0.0004 Tw 0 -1.18 TD (Drug Interactions )Tj 0.0002 Tc -0.0002 Tw 0 -1.17 TD (Effects of Other Drugs on VIAGRA )Tj /TT2 1 Tf 0.0009 Tc -0.0009 Tw T* (In vitro)Tj /TT1 1 Tf 0.0006 Tc -0.0006 Tw ( studies:)Tj /TT0 1 Tf 0.001 Tc -0.001 Tw 6.625 0 Td [( Sildenafil m)8.8 (etabolism)8.8 ( is principally )]TJ 0.0005 Tc -0.0005 Tw 14.82 0 Td [(m)8.3 (e)-0.7 (diated by the cytochrom)8.3 (e)-0.7 ( P450 \(CYP\) )]TJ 0.0006 Tc -0.0006 Tw -21.445 -1.165 Td [(isoform)8.4 (s 3A4 \(m)8.4 (ajor route\) and 2C9 \(m)8.4 (inor rout)-1.8 (e\). Therefore, inhibitors of these isoenzym)8.5 (es )]TJ 0.001 Tc -0.001 Tw 0 -1.165 TD [(m)8.8 (ay reduce sildenafil clearance.
Teva sildenafil pills are white, not blue
)]TJ 0 Tc 0 Tw T* ( )Tj /TT2 1 Tf 0.0008 Tc -0.0008 Tw 0 -1.18 TD (In vivo)Tj /TT1 1 Tf 0.0006 Tc -0.0006 Tw 2.865 0 Td ( studies:)Tj /TT0 1 Tf 3.535 0 Td [( Cim)8.5 (etidine \(800 m)8.5 (g)0.7 (\), a nonspecific CYP inhibitor, caused a 56% increase in )]TJ -6.4 -1.165 Td [(plasm)8.4 (a)-0.6 ( sildenafil concentrations when coadm)8.4 (i)-1.6 (nistered with VIAGRA \(50 m)8.4 (g)0.6 (\) to healthy )]TJ 0.0009 Tc 0 Tw 0 -1.165 TD (volunteers. )Tj 0 Tc T* ( )Tj 0.0001 Tc -0.0001 Tw T* [(W)8.9 (hen a single 100 m)7.9 (g dose of VIAGRA was adm)7.9 (i)]TJ 0.0008 Tc -0.0008 Tw 20.335 0 Td [(nistered with erythrom)8.6 (ycin, a specific )]TJ 0.0007 Tc -0.0007 Tw -20.335 -1.165 Td [(CYP3A4 inhibitor, at steady state \(500 m)8.5 (g)0.7 ( bid for 5 days\), there was a 182% increase in )]TJ T* [(sildenafil system)8.5 (ic exposure \(AUC\). In addition, in a study perform)8.5 (ed in healthy m)8.5 (ale )]TJ T* [(volunteers, coadm)8.5 (i)-1.5 (nistration of the HIV protease i)-1.1 (nhibitor saquinavir, also a CYP3A4 sildenafil oral solution inhibitor, )]TJ T* [(at steady state \(1200 m)8.5 (g)0.7 ( tid\) with VIAGRA \(100 m)8.5 (g)0.7 ( single dose\) resulted in a 140% increase in )]TJ ET /Artifact <>BDC Q q 1 0 0 1 120.6970062 785.2004395 cm /GS1 gs /Fm0 Do Q EMC /Artifact <>BDC q 1 0 0 1 612 773.2004395 cm /GS1 gs /Fm1 Do Q EMC endstream endobj 312 0 obj <>>>/Resources 325 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 65.791 -7.9 Td (This ) Tj 22.92 0 Td (label ) Tj 26.055 0 Td (may ) Tj 22.71 0 Td (not ) Tj 18.12 0 Td (be ) Tj 14.692 0 Td (the ) Tj 18.023 0 Td (latest ) Tj 29.595 0 Td (approved ) Tj 48.974 0 Td (by ) Tj 14.17 0 Td (FDA. ) Tj -281.05 -12 Td (For ) Tj 18.96 0 Td (current ) Tj 38.765 0 Td (labeling ) Tj 41.055 0 Td (information, ) Tj 61.25 0 Td (please ) Tj 34.707 0 Td (visit ) Tj 22.299 0 Td ( Tj ET endstream endobj 313 0 obj <>>>/Resources 327 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 0 -7.9 Td ( ) Tj ET endstream endobj 327 0 obj <> endobj 328 0 obj <> endobj 326 0 obj <>stream /This label may not be the latest approved by FDA. For current labeling information, please visit endstream endobj 325 0 obj <> endobj 329 0 obj <> endobj 324 0 obj <>stream /This label may not be the latest approved by FDA. In addition, in a study perform)8.5 (ed in healthy m)8.5 (ale )]TJ T* [(volunteers, coadm)8.5 (i)-1.5 (nistration of the HIV protease i)-1.1 (nhibitor saquinavir, also a CYP3A4 sildenafil oral solution inhibitor, )]TJ T* [(at steady state \(1200 m)8.5 (g)0.7 ( tid\) with VIAGRA \(100 m)8.5 (g)0.7 ( single dose\) resulted in a 140% increase in )]TJ ET /Artifact <>BDC Q q 1 0 0 1 120.6970062 785.2004395 cm /GS1 gs /Fm0 Do Q EMC /Artifact <>BDC q 1 0 0 1 612 773.2004395 cm /GS1 gs /Fm1 Do Q EMC endstream endobj 312 0 obj <>>>/Resources 325 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 65.791 -7.9 Td (This ) Tj 22.92 0 Td (label ) Tj 26.055 0 Td (may ) Tj 22.71 0 Td (not ) Tj 18.12 0 Td (be ) Tj 14.692 0 Td (the ) Tj 18.023 0 Td (latest ) Tj 29.595 0 Td (approved ) Tj 48.974 0 Td (by ) Tj 14.17 0 Td (FDA. ) Tj -281.05 -12 Td (For ) Tj 18.96 0 Td (current ) Tj 38.765 0 Td (labeling ) Tj 41.055 0 Td (information, ) Tj 61.25 0 Td (please ) Tj 34.707 0 Td (visit ) Tj 22.299 0 Td ( Tj ET endstream endobj 313 0 obj <>>>/Resources 327 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 0 -7.9 Td ( ) Tj ET endstream endobj 327 0 obj <> endobj 328 0 obj <> endobj 326 0 obj <>stream /This label may not be the latest approved by FDA. For current labeling information, please visit endstream endobj 325 0 obj <> endobj 329 0 obj <> endobj 324 0 obj <>stream /This label may not be the latest approved by FDA. For current labeling information, please visit endstream endobj 311 0 obj <> endobj 306 0 obj <>stream q 1 0 0 1 -8.008606 -1.877228 cm 0 0 612 792 re W n 1 0 0 1 8.008606 1.877228 cm BT /GS0 gs /TT0 1 Tf 12 0 0 12 63.9914 47.6228 Tm ( )Tj 19 -0.005 Td (12)Tj 0.0008 Tc -0.0008 Tw -19 54.94 Td [(- In those patients already taking an optim)8.6 (ized dose of a PDE5 inhibitor, alpha-blocker therapy )]TJ 0 -1.165 TD [(should be initiated at the lowest dose.
| Condition | Risk | Recommendation |
|---|---|---|
| Nitrate Use | Severe hypotension | Avoid combination |
| Heart Disease | Increased risk of cardiac event | Consult physician |
| Liver or Kidney Impairment | Altered drug metabolism | Dose adjustment necessary |
| Retinitis Pigmentosa | Potential for increased visual side effects | Use with caution |
Stepwise increase in alpha-block\ er dose m)8.6 (ay be associated )]TJ 0.0005 Tc -0.0005 Tw T* (with further lowering of blood pressure when taking a PDE5 inhibitor. )Tj T* [(- Safety of com)8.3 (b)0.5 (ined use of PDE5 inhibitors and alpha-blockers m)8.3 (a)-0.7 (y be affected by other )]TJ 0.0009 Tc -0.0009 Tw T* [(variables, including intravascular volum)8.7 (e depletion and other anti-hypertensive drugs. )]TJ 0 Tc 0 Tw T* ( )Tj 0.0007 Tc -0.0007 Tw T* [(Viagra has system)8.5 (ic vasodilatory properties and m)8.5 (ay augm)8.5 (ent the blood pressure lowering effect )]TJ 0.0009 Tc -0.0009 Tw T* [(of other anti-hypertensive m)8.7 (edications.
Sildenafil Overdose
Tadalis Sx
)]TJ 0 Tc 0 Tw T* ( )Tj 0.001 Tc -0.001 Tw T* [(Patients on m)8.8 (u)1 (ltiple antihypertensive m)8.8 (edications were included in the pivotal clinical trials for )]TJ 0.0004 Tc -0.0004 Tw T* (VIAGRA. In a separate drug interaction study, wh)Tj 0.0002 Tc -0.0002 Tw 20.21 0 Td [(en am)8 (lodipine, 5 m)8 (g or 10 m)8 (g, and VIAGRA, )]TJ 0.0008 Tc -0.0008 Tw -20.21 -1.165 Td [(100 m)8.6 (g)0.8 ( were orally adm)8.6 (i)-1.4 (nistered concom)8.6 (itantly to hypertensive patients m)8.6 (ean additional blood )]TJ 0.0007 Tc -0.0007 Tw 0 -1.18 TD [(pressure reduction of 8 m)8.5 (m)8.5 (H)2.9 (g systolic and 7 m)8.5 (m)8.5 (H)2.9 (g diastolic were noted \(see )]TJ /TT1 1 Tf -0.0006 Tc 0 Tw 31.42 0 Td (Drug )Tj 0.0006 Tc -31.42 -1.18 Td (Interactions)Tj /TT0 1 Tf 0.001 Tc 5.175 0 Td (\). )Tj 0 Tc -5.175 -1.165 Td ( )Tj 0.0005 Tc -0.0005 Tw 0 -1.165 TD (The safety of VIAGRA is unknown in patients with bleeding disorders and \ patients with active )Tj 0.001 Tc -0.001 Tw T* (peptic ulceration.
5.5 Hearing Loss
)Tj 0 Tc 0 Tw T* ( )Tj 0.0005 Tc -0.0005 Tw T* [(VIAGRA should be used with caution in patients with anatom)8.3 (ical deform)8.3 (ation of the penis \(such )]TJ 0.0008 Tc -0.0008 Tw T* (as angulation, cavernosal fibrosis or Peyronie\222s disease\), or in pat\ ients who have conditions )Tj 0.0009 Tc -0.0009 Tw T* [(which m)8.7 (ay predispose them)8.7 ( to priapism)8.7 ( \(such as sickle cell anem)8.7 (ia, m)8.7 (u)0.9 (ltiple m)8.7 (y)0.9 (elom)8.7 (a, or )]TJ 0 Tw T* [(leukem)8.7 (i)-1.3 (a\).
Inform MD
)]TJ 0 Tc T* ( )Tj 0.0003 Tc -0.0003 Tw T* [(The safety and efficacy of com)8.1 (binations of)]TJ 0.0006 Tc -0.0006 Tw 17.16 0 Td [( VIAGRA with other treatm)8.4 (e)-0.6 (nts for erectile )]TJ 0.0005 Tc -0.0005 Tw -17.16 -1.165 Td (dysfunction have not been studied.